Linda Jaccarino Joins EMED as CEO
Linda Jaccarino, the former CEO of X, has taken on a new position leading a digital health startup, EMED Population Health, based in Miami.
The 61-year-old will head a company that’s focused on providing resources and support to patients utilizing Ozempic and other GLP-1 medications for treating obesity and diabetes.
EMED highlighted Jaccarino’s strong negotiation skills with potential partners as a key reason for her appointment, especially as the company looks to secure more collaborations with employers and governmental bodies.
In a statement, Jaccarino noted, “The healthcare industry is disrupted by technology, but it has not yet completely transformed.” She elaborated, mentioning that there’s a significant opportunity to merge data in innovative ways via digital channels, enabling direct consumer impact like never before.
Jaccarino’s resignation from X occurred last month after a turbulent two-year tenure, during which the platform faced intense scrutiny for its management, notably regarding its ties to former President Trump’s administration.
Her departure coincided with a controversial incident involving an anti-Semitic remark linked to X’s Grok chatbot, which was dubbed “Mecha Hitler.” However, sources indicated that her exit was already planned and unrelated to this event.
A source mentioned, “She got her advertisers back and made a profit again,” adding that she felt it was the right time to move on.
Before joining X in 2023, shortly after Elon Musk’s acquisition of the platform formerly known as Twitter, Jaccarino was a leading figure in advertising at NBCUniversal. Her role included efforts to mend relationships with major corporate advertisers that were affected by the changes Musk implemented.
While at X, she was involved in filing a federal antitrust lawsuit against a global advertising federation associated with the shadow organization known as GARM.
According to EMED’s press release, the company offers services like “home diagnosis, Proctor-led screening and doctor-guided prescriptions,” claiming its approach could potentially cut weight loss program costs by up to 50%.
